Stoke Therapeutics, Inc.
For the period ended Dec 31, 2024. Filed Mar 18, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 18, 2025
STOK$27.21-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated statements of stockholders’ equity
| Common Stock · Additional paid-in capital · Accumulated Other Comprehensive Gain (Loss) · Accumulated deficit · Total 'Stockholders’ equity | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2022 | 39,439,575 | $4 | $483,170 | $(1,175) | $(297,150) | $184,849 |
| Unrealized gain on marketable securities | — | — | — | 1,151 | — | 1,151 |
| Stock-based compensation | — | — | 25,257 | — | — | 25,257 |
| Issuance of common stock upon exercise of stock options | 148,211 | — | 371 | — | — | 371 |
| Issuance of common stock related to employee stock purchase plan | 71,471 | — | 555 | — | — | 555 |
| Shares sold as part of controlled equity offering sales agreement, net of commissions | 6,258,976 | 1 | 52,080 | — | — | 52,081 |
| Net loss | — | — | — | — | (104,699) | (104,699) |
| Balance as of December 31, 2023 | 45,918,233 | $5 | $561,433 | $(24) | $(401,849) | $159,565 |
| Unrealized loss on marketable securities | — | — | — | (127) | — | (127) |
| Stock-based compensation | — | — | 27,470 | — | — | 27,470 |
| Issuance of common stock upon exercise of stock options | 825,187 | — | 1,722 | — | — | 1,722 |
| Issuance of common stock related to employee stock purchase plan | 110,641 | — | 532 | — | — | 532 |
| Issuance of common stock and warrants upon follow-on offering, net of underwriting discounts, commissions, and offering costs | 5,555,557 | — | 119,884 | — | — | 119,884 |
| Issuance of vested restricted stock units and performance stock units | 841,238 | — | — | — | — | — |
| Shares sold as part of controlled equity offering sales agreement, net of commissions | 781,970 | — | 8,956 | — | — | 8,956 |
| Net loss | — | — | — | — | (88,981) | (88,981) |
| Balance as of December 31, 2024 | 54,032,826 | $5 | $719,997 | $(151) | $(490,830) | $229,021 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.